Pharmacists have raised concerns that the demand for weight loss medications is becoming “unsustainable,” potentially leading to a situation where demand exceeds supply.
The National Pharmacy Association (NPA) highlighted that these supply challenges might push individuals to seek out unregulated online options, despite the associated risks.
In the UK, the use of medications like Wegovy and Mounjaro has surged to over a million, with the majority of users opting to pay privately. In April alone, around 1.6 million packs of these drugs were purchased, a number that reflects the growing user base.
The NPA cautioned that the increasing demand for weight loss treatments is reaching levels that may not be clinically sustainable. They suggested that these medications should be prioritized for those who are severely overweight rather than the “worried well.”
Recent polling indicates that 21% of British individuals attempted to procure these medications in the past year, with this number climbing to 35% among younger adults aged 18 to 34.
Interestingly, 41% of respondents across all age groups expressed willingness to use the medications if they were available for free through the NHS, and this figure jumped to 64% among those aged 25-34.
The NPA, which represents 6,000 independent pharmacies, commissioned a survey of 2,002 adults conducted online between June 20 and June 23.
Olivier Picard, chair of the NPA, remarked that while weight loss injections represent a significant advancement in the field of medicine, the mounting interest underscores the importance of ensuring that such treatments are appropriate for those in need.
He also noted that the survey results reveal a greater interest in weight loss injections than the number of individuals who can genuinely benefit from medical weight loss interventions.
Supply issues have emerged, particularly for the higher doses of Mounjaro, leading to restrictions in some pharmacies and preventing new patients from accessing these treatments.
The Medicines and Healthcare products Regulatory Agency, the UK’s regulatory body for drugs, has cautioned patients to acquire these medications only through a doctor’s prescription, steering clear of beauty salons or unverified websites.
A government spokesperson from the Department of Health indicated that more individuals will have access to these “revolutionary” weight loss drugs over the coming years, emphasizing their role in addressing the obesity crisis as part of a broader health initiative.
They assured that the government is dedicated to ensuring safe access to these medications, prioritizing those who require treatment most urgently.
In England, around 220,000 people are expected to be offered tirzepatide, a diabetes medication that facilitates weight loss, within the next three years.
Picard stressed that pharmacies, which currently provide about 85% of all weight loss medications, should play a vital role in increasing access to these treatments for those in need.
He suggested that the government capitalize on the significant expertise and skills of pharmacists to expedite the NHS’s weight loss medication program for millions of patients requiring assistance.
